Australia Schedules BPC-157 as a Controlled Substance
Australia TGA placed BPC-157 in Schedule 10 in 2023, banning its sale and import. What the scheduling decision says and how it affects international buyers.
Australia's Therapeutic Goods Administration finalized a decision in 2024 to schedule BPC-157 as a prescription-only substance under Schedule 4 of the Poisons Standard. The change took effect on June 1, 2024, making Australia one of the first countries to specifically regulate BPC-157 by name. The decision followed a November 2023 committee meeting that considered 48 import referrals the TGA had received since July 2022.
What the TGA Decided
The Advisory Committee on Medicines Scheduling (ACMS #43) met in November 2023 and recommended creating a new Schedule 4 entry for BPC-157. The TGA Delegate confirmed the final decision in early 2024, with an implementation date of June 1, 2024. The scheduling aligns BPC-157 with other performance- and image-enhancing substances already regulated in Australia.
The major factors that contributed to the decision involve the high risk of abuse as relates to athletes, fitness, wellness, and anti-aging sectors. In addition, the committee mentioned the WADA decision to place BPC-157 on the prohibited list all the time under S0.
Schedule 4 Explained
The Poisons Standard of Australia includes Schedule 4 list of prescription-only medicine. Having possession of a Schedule 4 item without a valid prescription, or any other form of authorization (like a research license) is against the law according to different state and territory laws. The charges and penalties might differ based on states and territories but can range from fines to criminal imprisonment.
This regulation appears to be more severe than what is practiced in the United States. There, BPC-157 is regarded as a research chemical which does not require a prescription for possession. Australia treats BPC-157 as if it were a legally regulated pharmaceutical product, as opposed to a research chemical.
- Category
- Schedule 4 (Prescription Only)
- Effective date
- June 1, 2024
- Committee
- ACMS #43, November 2023
- Import referrals cited
- 48 since July 2022
- Rationale
- Misuse risk, WADA S0 listing
Import and Customs Implications
Australian Border Force is cooperating with the TGA in stopping unapproved therapeutic items at the border. Importing BPC-157 into Australia without a valid permit or prescription has been against the Therapeutic Goods Act since June 2024. Prior to the formal scheduling, the TGA was already intercepting shipments of BPC-157, as evidenced by 48 reports between July 2022 and November 2023.
Shipment of items containing BPC-157 has a potential risk of seizure. Authorities, including the TGA and the relevant state authorities, may decide to follow up with the importer.
How Other Countries Compare
| Country | BPC-157 Status | Notes |
|---|---|---|
| United States | Unscheduled | Available as a research chemical. Not FDA-approved for human use. FDA placed BPC-157 on the Category 2 bulk drug substance list. |
| Australia | Schedule 4 (Rx only) | Prescription required since June 1, 2024. Import restricted. |
| United Kingdom | Not specifically scheduled | Falls under general medicines regulations. Not approved for human use. |
| Canada | Not specifically scheduled | Not approved. Health Canada has not issued specific scheduling. |
| European Union | Varies by member state | Not approved. No EU-wide scheduling. Some countries restrict import. |
Australia's decision is the most explicit regulatory action taken against BPC-157 by any single country. The United States has not scheduled BPC-157 but the FDA has signaled increased attention through its Category 2 classification. For a broader look at what these classifications mean for buying, see our prescription vs no prescription comparison.
FAQ - BPC-157 in Australia
Is BPC-157 legal in Australia?
BPC-157 is classified as a Schedule 4 controlled substance under Australian law from June 1, 2024. It is prohibited to possess this substance if you lack the appropriate prescription or authorization from TGA or Border Force.
When did Australia ban BPC-157?
The TGA's ACMS #43 committee recommended scheduling in November 2023. The Delegate confirmed the final decision in early 2024, with the Schedule 4 entry taking effect on June 1, 2024.
Can I import BPC-157 into Australia?
Not without an appropriate authorization. Since the Schedule 4 classification, importing BPC-157 requires a valid prescription or a research permit. The TGA had already been intercepting shipments before the formal scheduling.
What happens if customs finds BPC-157?
The package can be confiscated by the Australian Border Force, and the case may be reported to the TGA. The importer could be subject to an investigation or penalties based on the amount of importation, the relevant jurisdiction, and whether the package has been imported previously.
Are other countries following Australia?
No other country has yet matched Australia's explicit scheduling of BPC-157. However, WADA's 2022 S0 classification and the FDA's Category 2 listing suggest regulatory attention is increasing. Buyers in any country should check local laws before ordering.
Keep reading
Online Peptide Market Grows as New Vendors Enter in 2026
The online research peptide market expanded in 2026 with new vendors and COA databases. How market growth affects BPC-157 pricing and availability.
GMP Certification in Peptide Manufacturing: What It Means
What GMP certification means for peptide manufacturing. How current Good Manufacturing Practice standards apply to research peptide vendors and what buyers can verify.
Five Common Peptide Reconstitution Mistakes to Avoid
Five common errors when reconstituting lyophilized peptides like BPC-157. Wrong water type, excessive force, temperature mistakes and contamination risks.
Compare the current picks
Prices, sizes and ratings side by side, updated when the merchant pages change.
Shop BPC-157